Clinical trials: Borderline Resectable Pancreatic Adenocarcinoma
- Condition Borderline Resectable Pancreatic Adenocarcinoma
- Funder type Industry (pharma, biotech, devices)
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT06673017
- Testing
- PTM-101
- Where
- 9 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- PanTher Therapeutics
Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being…
- Trial name
- PaTK02 (NCT02446093)
- Testing
- Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy
- Where
- 3 sites in United States, Mexico
- Volunteers
- 54 people
- Sponsor
- Candel Therapeutics, Inc.